Corcept Therapeutics CORT Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's change in accrued liabilities?
- Corcept Therapeutics (CORT) reported change in accrued liabilities of -$9.38M in Q1 2026.
- How has Corcept Therapeutics's change in accrued liabilities changed year-over-year?
- Corcept Therapeutics's change in accrued liabilities decreased by 59.7% year-over-year, from -$5.87M to -$9.38M.
- What is the long-term trend for Corcept Therapeutics's change in accrued liabilities?
- Over 2 years (2021 to 2024), Corcept Therapeutics's change in accrued liabilities has grown at a 146.8% compound annual growth rate (CAGR), from $6.48M to $39.45M.
- What does change in accrued liabilities mean?
- The net change in short-term unpaid operational expenses.
- How do you interpret change in accrued liabilities?
- An increase indicates growing operational obligations, while a decrease reflects the clearing of accrued expenses.
- How does change in accrued liabilities compare across companies?
- Standard across all sectors; reflects general operational accrual accounting practices.